129 related articles for article (PubMed ID: 29079470)
1. Small molecule alteration of RNA sequence in cells and animals.
Guan L; Luo Y; Ja WW; Disney MD
Bioorg Med Chem Lett; 2018 Sep; 28(16):2794-2796. PubMed ID: 29079470
[TBL] [Abstract][Full Text] [Related]
2. Precise small-molecule recognition of a toxic CUG RNA repeat expansion.
Rzuczek SG; Colgan LA; Nakai Y; Cameron MD; Furling D; Yasuda R; Disney MD
Nat Chem Biol; 2017 Feb; 13(2):188-193. PubMed ID: 27941760
[TBL] [Abstract][Full Text] [Related]
3. Rationally designed small molecules that target both the DNA and RNA causing myotonic dystrophy type 1.
Nguyen L; Luu LM; Peng S; Serrano JF; Chan HY; Zimmerman SC
J Am Chem Soc; 2015 Nov; 137(44):14180-9. PubMed ID: 26473464
[TBL] [Abstract][Full Text] [Related]
4. A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.
Reddy K; Jenquin JR; McConnell OL; Cleary JD; Richardson JI; Pinto BS; Haerle MC; Delgado E; Planco L; Nakamori M; Wang ET; Berglund JA
Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20991-21000. PubMed ID: 31570586
[TBL] [Abstract][Full Text] [Related]
5. A Small Molecule that Binds an RNA Repeat Expansion Stimulates Its Decay via the Exosome Complex.
Angelbello AJ; Benhamou RI; Rzuczek SG; Choudhary S; Tang Z; Chen JL; Roy M; Wang KW; Yildirim I; Jun AS; Thornton CA; Disney MD
Cell Chem Biol; 2021 Jan; 28(1):34-45.e6. PubMed ID: 33157036
[TBL] [Abstract][Full Text] [Related]
6. Development of pharmacophore models for small molecules targeting RNA: Application to the RNA repeat expansion in myotonic dystrophy type 1.
Angelbello AJ; González ÀL; Rzuczek SG; Disney MD
Bioorg Med Chem Lett; 2016 Dec; 26(23):5792-5796. PubMed ID: 27839685
[TBL] [Abstract][Full Text] [Related]
7. Features of modularly assembled compounds that impart bioactivity against an RNA target.
Rzuczek SG; Gao Y; Tang ZZ; Thornton CA; Kodadek T; Disney MD
ACS Chem Biol; 2013 Oct; 8(10):2312-21. PubMed ID: 24032410
[TBL] [Abstract][Full Text] [Related]
8. Single-molecule study of the CUG repeat-MBNL1 interaction and its inhibition by small molecules.
Haghighat Jahromi A; Honda M; Zimmerman SC; Spies M
Nucleic Acids Res; 2013 Jul; 41(13):6687-97. PubMed ID: 23661680
[TBL] [Abstract][Full Text] [Related]
9. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
[TBL] [Abstract][Full Text] [Related]
10. Optimization of the Linker Domain in a Dimeric Compound that Degrades an r(CUG) Repeat Expansion in Cells.
Benhamou RI; Abe M; Choudhary S; Meyer SM; Angelbello AJ; Disney MD
J Med Chem; 2020 Jul; 63(14):7827-7839. PubMed ID: 32657583
[TBL] [Abstract][Full Text] [Related]
11. Macrocyclization of a Ligand Targeting a Toxic RNA Dramatically Improves Potency.
Benhamou RI; Vezina-Dawod S; Choudhary S; Won Wang K; Meyer SM; Yildirim I; Disney MD
Chembiochem; 2020 Nov; 21(22):3229-3233. PubMed ID: 32649032
[TBL] [Abstract][Full Text] [Related]
12. Studying a Drug-like, RNA-Focused Small Molecule Library Identifies Compounds That Inhibit RNA Toxicity in Myotonic Dystrophy.
Rzuczek SG; Southern MR; Disney MD
ACS Chem Biol; 2015 Dec; 10(12):2706-15. PubMed ID: 26414664
[TBL] [Abstract][Full Text] [Related]
13. Comparison of small molecules and oligonucleotides that target a toxic, non-coding RNA.
Costales MG; Rzuczek SG; Disney MD
Bioorg Med Chem Lett; 2016 Jun; 26(11):2605-9. PubMed ID: 27117425
[TBL] [Abstract][Full Text] [Related]
14. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1.
de Haro M; Al-Ramahi I; De Gouyon B; Ukani L; Rosa A; Faustino NA; Ashizawa T; Cooper TA; Botas J
Hum Mol Genet; 2006 Jul; 15(13):2138-45. PubMed ID: 16723374
[TBL] [Abstract][Full Text] [Related]
15. Structure of the myotonic dystrophy type 2 RNA and designed small molecules that reduce toxicity.
Childs-Disney JL; Yildirim I; Park H; Lohman JR; Guan L; Tran T; Sarkar P; Schatz GC; Disney MD
ACS Chem Biol; 2014 Feb; 9(2):538-550. PubMed ID: 24341895
[TBL] [Abstract][Full Text] [Related]
16. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.
Wojtkowiak-Szlachcic A; Taylor K; Stepniak-Konieczna E; Sznajder LJ; Mykowska A; Sroka J; Thornton CA; Sobczak K
Nucleic Acids Res; 2015 Mar; 43(6):3318-31. PubMed ID: 25753670
[TBL] [Abstract][Full Text] [Related]
17. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
Zhang F; Bodycombe NE; Haskell KM; Sun YL; Wang ET; Morris CA; Jones LH; Wood LD; Pletcher MT
Hum Mol Genet; 2017 Aug; 26(16):3056-3068. PubMed ID: 28535287
[TBL] [Abstract][Full Text] [Related]
18. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2.
Mankodi A; Urbinati CR; Yuan QP; Moxley RT; Sansone V; Krym M; Henderson D; Schalling M; Swanson MS; Thornton CA
Hum Mol Genet; 2001 Sep; 10(19):2165-70. PubMed ID: 11590133
[TBL] [Abstract][Full Text] [Related]
19. Methods to enable the design of bioactive small molecules targeting RNA.
Disney MD; Yildirim I; Childs-Disney JL
Org Biomol Chem; 2014 Feb; 12(7):1029-39. PubMed ID: 24357181
[TBL] [Abstract][Full Text] [Related]
20. A Ligand That Targets CUG Trinucleotide Repeats.
Li J; Matsumoto J; Bai LP; Murata A; Dohno C; Nakatani K
Chemistry; 2016 Oct; 22(42):14881-14889. PubMed ID: 27573860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
